European Observational Study on Lebrikizumab Impact for Adults with Moderate-to-Severe Atopic Dermatitis Assessing Well-Being and Skin Symptom Control Over Two Years

What this Trial Is About

Researchers are evaluating the impact of lebrikizumab treatment on the overall well-being of adults with moderate-to-severe atopic dermatitis in real-world clinical settings across Europe. The study aims to measure health-related well-being using the World Health Organization Well-being Index WHO-5 and to assess lebrikizumabs effectiveness, safety, treatment satisfaction, and long-term effects on symptoms, fatigue, work impairment, skin relationships, and overall quality of life. Participants prescribed lebrikizumab as part of their usual care will be observed for 104 weeks. This is a non-interventional, observational study where data on participants receiving lebrikizumab will be collected according to routine clinical practice without altering their treatment. The study focuses on tracking health and symptom control over this two-year period. During the study, participants will undergo regular assessments of their well-being, eczema severity, itch and skin pain intensity, fatigue, sleep quality, and adverse events. Researchers will use validated scales including WHO-5, Eczema Area and Severity Index EASI, Investigator Global Assessment IGA, Patient-Oriented Eczema Measure POEM, and Numerical Rating Scales for pruritus, skin pain, and fatigue. Safety and treatment satisfaction will also be monitored throughout the 104 weeks of observation.

A Study to Assess the Impact of Lebrikizumab on Health-Related Well-Being and Control of Skin Manifestations in Participants With Moderate-to-Severe Atopic Dermatitis